Roth Capital Analysts Cut Earnings Estimates for Cresco Labs

Cresco Labs Inc. (OTCMKTS:CRLBF) – Equities researchers at Roth Capital reduced their Q2 2025 earnings estimates for Cresco Labs in a research report issued on Tuesday, June 3rd. Roth Capital analyst W. Kirk now expects that the company will post earnings per share of ($0.04) for the quarter, down from their prior estimate of ($0.02). The consensus estimate for Cresco Labs’ current full-year earnings is ($0.20) per share. Roth Capital also issued estimates for Cresco Labs’ Q3 2025 earnings at ($0.03) EPS, Q4 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.14) EPS and FY2026 earnings at ($0.13) EPS.

Cresco Labs (OTCMKTS:CRLBF) last announced its quarterly earnings data on Friday, May 30th. The company reported ($0.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.01). Cresco Labs had a negative return on equity of 16.52% and a negative net margin of 9.15%. The firm had revenue of $165.76 million during the quarter, compared to analysts’ expectations of $164.37 million.

A number of other equities research analysts have also weighed in on the stock. Canaccord Genuity Group lowered shares of Cresco Labs from a “strong-buy” rating to a “moderate buy” rating in a research note on Tuesday. Cormark raised shares of Cresco Labs from a “hold” rating to a “moderate buy” rating in a research report on Monday, March 17th. Two equities research analysts have rated the stock with a hold rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Cresco Labs presently has an average rating of “Buy”.

Cresco Labs Price Performance

Shares of CRLBF opened at $0.51 on Thursday. The firm has a market cap of $250.42 million, a PE ratio of -2.55 and a beta of 1.73. The company has a current ratio of 1.97, a quick ratio of 1.39 and a debt-to-equity ratio of 1.80. The firm has a fifty day simple moving average of $0.70 and a two-hundred day simple moving average of $0.85. Cresco Labs has a 1-year low of $0.49 and a 1-year high of $2.05.

About Cresco Labs

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.